Last reviewed · How we verify
favorable outcome — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
favorable outcome (favorable outcome) — Centre d'Investigation Clinique et Technologique 805.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| favorable outcome TARGET | favorable outcome | Centre d'Investigation Clinique et Technologique 805 | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- favorable outcome CI watch — RSS
- favorable outcome CI watch — Atom
- favorable outcome CI watch — JSON
- favorable outcome alone — RSS
Cite this brief
Drug Landscape (2026). favorable outcome — Competitive Intelligence Brief. https://druglandscape.com/ci/favorable-outcome. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing